JP2020520956A - 聴力損失の治療における使用のためのニューロトロフィン - Google Patents

聴力損失の治療における使用のためのニューロトロフィン Download PDF

Info

Publication number
JP2020520956A
JP2020520956A JP2019564510A JP2019564510A JP2020520956A JP 2020520956 A JP2020520956 A JP 2020520956A JP 2019564510 A JP2019564510 A JP 2019564510A JP 2019564510 A JP2019564510 A JP 2019564510A JP 2020520956 A JP2020520956 A JP 2020520956A
Authority
JP
Japan
Prior art keywords
neurotrophin
ngf
use according
hearing loss
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019564510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020520956A5 (https=
Inventor
デ ピッツォル マリア
デ ピッツォル マリア
アラミニ アンドリア
アラミニ アンドリア
シリコ アンナ
シリコ アンナ
ツィッポリ マラ
ツィッポリ マラ
アチェッラ ジュゼッピーナ
アチェッラ ジュゼッピーナ
ルカ マッティオーリ シモーネ
ルカ マッティオーリ シモーネ
Original Assignee
ドンペ ファーマスーチシ ソシエタ ペル アチオニ
ドンペ ファーマスーチシ ソシエタ ペル アチオニ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ドンペ ファーマスーチシ ソシエタ ペル アチオニ, ドンペ ファーマスーチシ ソシエタ ペル アチオニ filed Critical ドンペ ファーマスーチシ ソシエタ ペル アチオニ
Publication of JP2020520956A publication Critical patent/JP2020520956A/ja
Publication of JP2020520956A5 publication Critical patent/JP2020520956A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019564510A 2017-05-24 2018-05-22 聴力損失の治療における使用のためのニューロトロフィン Pending JP2020520956A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17172659.9A EP3406259A1 (en) 2017-05-24 2017-05-24 Neurotrophins for use in the treatment of hearing loss
EP17172659.9 2017-05-24
PCT/EP2018/063310 WO2018215414A1 (en) 2017-05-24 2018-05-22 Neurotrophins for use in the treatment of hearing loss

Publications (2)

Publication Number Publication Date
JP2020520956A true JP2020520956A (ja) 2020-07-16
JP2020520956A5 JP2020520956A5 (https=) 2021-08-12

Family

ID=58772736

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019564510A Pending JP2020520956A (ja) 2017-05-24 2018-05-22 聴力損失の治療における使用のためのニューロトロフィン

Country Status (11)

Country Link
US (1) US20200155647A1 (https=)
EP (2) EP3406259A1 (https=)
JP (1) JP2020520956A (https=)
KR (1) KR20200011951A (https=)
CN (1) CN110691607A (https=)
AU (1) AU2018274589A1 (https=)
BR (1) BR112019024504A2 (https=)
CA (1) CA3062744A1 (https=)
IL (1) IL270701A (https=)
RU (1) RU2019137430A (https=)
WO (1) WO2018215414A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514176A (ja) * 2021-04-13 2024-03-28 ドンペ・ファルマチェウティチ・ソシエタ・ペル・アチオニ Ｎｇｆを用いた神経障害性角膜疼痛の処置

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4093387A4 (en) * 2020-01-24 2024-04-24 Dompé farmaceutici S.p.A. GROWTH FACTOR FORMULATION FOR A CONDITION ASSOCIATED WITH AN OTIC EVENT
PL4452267T3 (pl) * 2021-12-23 2025-06-23 Cilcare Dev Pochodne 4-fenylo-tetrahydropirydyny do leczenia chorób słuchu
EP4316505A1 (en) * 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
KR102851394B1 (ko) * 2022-11-11 2025-09-04 단국대학교 천안캠퍼스 산학협력단 광반응성 하이드로젤을 이용한 분화유도인자 탑재 나노캡슐
EP4501346A1 (en) * 2023-08-04 2025-02-05 Dompe' Farmaceutici S.P.A. Method for the prevention of hearing loss induced by a platinum-based chemotherapy drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505671A (ja) * 1997-06-13 2002-02-19 ジェネンテック・インコーポレーテッド 制御放出マイクロカプセル化ｎｇｆ製剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225282B1 (en) * 1996-01-05 2001-05-01 Genentech, Inc. Treatment of hearing impairments
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
US7700111B2 (en) * 2002-01-17 2010-04-20 The Regents Of The University Of Michigan Auditory nerve protection and re-growth
WO2009062149A1 (en) * 2007-11-08 2009-05-14 Creighton University Methods for maintaining inner ear neurons
CN104203264B (zh) 2011-12-19 2018-08-28 瓦克化学有限公司 新型proNGF突变体及其在生产β-NGF中的用途
EP3328440A4 (en) * 2015-07-28 2019-01-16 Otonomy, Inc. TREATMENT WITH REDUCED TRK-B AND TRK-C ANTAGONISTS
CA2993645A1 (en) * 2015-07-28 2017-02-02 Otonomy, Inc. Trkb or trkc agonist compositions and methods for the treatment of otic conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505671A (ja) * 1997-06-13 2002-02-19 ジェネンテック・インコーポレーテッド 制御放出マイクロカプセル化ｎｇｆ製剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIN CHUNG ER BI YAN HOU TOU JING WAI KE ZA ZHI, vol. 30, no. 21, JPN6022009409, 5 November 2016 (2016-11-05), pages 1728 - 1731, ISSN: 0005058298 *
MOL CELL BIOCHEM, vol. 428, JPN6022043514, 7 January 2017 (2017-01-07), pages 149 - 159, ISSN: 0005058299 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024514176A (ja) * 2021-04-13 2024-03-28 ドンペ・ファルマチェウティチ・ソシエタ・ペル・アチオニ Ｎｇｆを用いた神経障害性角膜疼痛の処置

Also Published As

Publication number Publication date
WO2018215414A1 (en) 2018-11-29
AU2018274589A1 (en) 2019-11-28
KR20200011951A (ko) 2020-02-04
RU2019137430A (ru) 2021-06-24
EP3630159A1 (en) 2020-04-08
IL270701A (en) 2020-01-30
CN110691607A (zh) 2020-01-14
CA3062744A1 (en) 2018-11-29
EP3406259A1 (en) 2018-11-28
RU2019137430A3 (https=) 2021-08-30
BR112019024504A2 (pt) 2020-06-23
US20200155647A1 (en) 2020-05-21

Similar Documents

Publication Publication Date Title
JP2020520956A (ja) 聴力損失の治療における使用のためのニューロトロフィン
US11013719B2 (en) Sunitinib formulations and methods for use thereof in treatment of glaucoma
Herran et al. In vivo administration of VEGF-and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson’s disease
CN109689027A (zh) 甘油三酯耳用制剂及其用途
García-Caballero et al. Photoreceptor preservation induced by intravitreal controlled delivery of GDNF and GDNF/melatonin in rhodopsin knockout mice
JP2001525316A (ja) ニュールツリンタンパク質産物を使用する難聴の予防および治療方法
JPH11504351A (ja) 神経膠細胞系由来神経栄養因子（ｇｄｎｆ）タンパク質産物を使用する感覚神経性聴力損失及び前庭障害の予防及び治療方法
KR20180037994A (ko) TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
Yu et al. Complete restoration of hearing loss and cochlear synaptopathy via minimally invasive, single-dose, and controllable middle ear delivery of brain-derived neurotrophic Factor–Poly (dl-lactic acid-co-glycolic acid)-loaded hydrogel
US6500449B2 (en) Intraocular transplantation of encapsulated cells
CA3087574A1 (en) Growth factor otic formulations
US20190374606A1 (en) Neurotrophin mutants for treating hearing loss and other otic disorders
KR20170030093A (ko) 결막하 및 눈주위 주사를 위한 사이클로스포린 a의 현탁액 조성물
JP2025525989A (ja) 感音性難聴の治療のためのｎｇｆの鼻腔内投与
US20180221451A1 (en) Long acting liraglutide compositions
US11471502B2 (en) Neuroprotective peptide
WO2021127275A1 (en) Gsk-3 modulator otic formulations
CN120754133B (zh) Ber-ApoEVs及其制备和应用
Karagoz et al. Producing Aflibercept Loaded Poly (Lactic Co Glycolic Acid)[Plga] Nanoparticles As A New Ocular Drug Delivery System and Its Challenges
US20230127694A1 (en) Neuroprotective peptide
Hu Survival and Axonal Regeneration of Retinal Ganglion Cells in a Mouse Optic Nerve Crush Model After a Delayed Cell-Based Intravitreal Co-Therapy with Ciliary Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor
WO2026089752A1 (en) Compositions and methods for microsphere delivery of therapeutic peptides
HK40006438A (en) Triglyceride otic formulations and uses thereof
MX2008004518A (en) Method of inhibiting angiogenesis by using ephrin b2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230516